FDA warns Public vs folic acid brand | Inquirer News

FDA warns Public vs folic acid brand

Unregistered tablets
/ 12:35 AM November 28, 2016

The Food and Drug Administration (FDA) is warning health professionals and the general public against the use of an unregistered brand of folic acid tablets.

In an advisory, the FDA said Puritan’s Pride Premium Folic Acid 400-microgram tablet, manufactured by Puritan’s Pride Inc. in Holbrook, New York, is not registered with the health agency.

ADVERTISEMENT

“This poses potential danger or injury to the consuming public,” the FDA said.

Folic acid is used as a supplement during pregnancy to prevent neural tube defects.

FEATURED STORIES

The importation, selling or offering for sale of such unregistered product is in violation of Republic Act No. 9711, or the Food and Drug Administration Act of 2009, the agency said.

It also warned establishments and outlets against selling the product, saying anyone found selling it would be penalized.

“Purchase medications only from FDA-licensed establishments,” the agency told consumers, adding: “Look for the FDA Registration number on the product label. Be reminded that the drug products registered with FDA Philippines bear in their labels information in English and/or Filipino for all consumers to understand.”

To report the continuous sale or distribution of unregistered health products, send an email to [email protected] or call (02) 807-8275, it said. —TINA G. SANTOS

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

Read Next
Don't miss out on the latest news and information.

Subscribe to INQUIRER PLUS to get access to The Philippine Daily Inquirer & other 70+ titles, share up to 5 gadgets, listen to the news, download as early as 4am & share articles on social media. Call 896 6000.

TAGS: FDA warning
For feedback, complaints, or inquiries, contact us.
Your subscription could not be saved. Please try again.
Your subscription has been successful.

News that matters

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.



© Copyright 1997-2023 INQUIRER.net | All Rights Reserved

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.